BridgeBio Pharma (BBIO) AI Stock Analysis

• Market Cap: $9.38B
• Dividend Yield: N/A
• Average Volume (3M): 2.77M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: 7.62%
• EPS Growth: -55.29%
• Country: US
• Employees: 725
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.95
• Shares Outstanding: 191,168,500
• 10 Day Avg. Volume: 3,871,433
• 30 Day Avg. Volume: 2,768,167
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 43.07
• Enterprise Value/Gross Profit: 44.49
• Enterprise Value/Ebitda: -15.78
• 1Y Price Target: $60.12
• Price Target Upside: 22.47% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19

• Rating: 53 Neutral
• Price Target: $47.00 ▼(-4.26% Downside)

BridgeBio Pharma's overall stock score is primarily influenced by its strong earnings call performance and positive technical analysis indicators. However, significant financial performance challenges, particularly in profitability and financial stability, weigh heavily on the score. The valuation remains a concern due to negative earnings and lack of dividend yield.

Positive Factors

Financial Performance

BridgeBio is well-positioned financially with cash on hand, a growing top-line, and flattening or declining expenses.

Market Leadership

Attruby is expected to become the market share leader in the ATTR-CM market, indicating strong potential for future growth.

Negative Factors

Investor Concerns

Despite strong quarterly growth, BBIO shares dropped over 10% after-hours, reflecting investor concern over the crowded bullish positioning.

Market Competition

Strong new patient demand for Attruby persists despite competition, yet investor concerns over market saturation remain prevalent.

BridgeBio Pharma Business Overview & Revenue Model

Company Description

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

How the Company Makes Money

BridgeBio Pharma generates revenue primarily through the development and commercialization of its therapeutic products. The company earns money through product sales once its therapies receive regulatory approval and are launched in the market. Additionally, BridgeBio may engage in partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on future sales. These strategic alliances can enhance revenue streams and provide necessary funding for ongoing research and development. Furthermore, BridgeBio may also receive grant funding for specific projects, contributing to its overall earnings.

BridgeBio Pharma Financial Statement Overview

Summary

BridgeBio Pharma demonstrates strong revenue growth but faces significant profitability and financial stability challenges. The high gross profit margin indicates efficient cost management, yet operational losses persist. The balance sheet reflects financial instability with negative equity, and while cash flow generation shows improvement, it remains negative overall. The company needs to address its profitability and leverage to enhance financial health.

Income Statement

BridgeBio Pharma shows a strong revenue growth rate of 54.42% in the TTM, indicating a positive trajectory in sales. However, the company faces significant profitability challenges with a negative net profit margin of -5.24% and EBIT margin of -4.38%, reflecting ongoing operational losses. The gross profit margin remains high at 96.95%, suggesting efficient cost management at the gross level.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity, resulting in an unusual debt-to-equity ratio of -0.006. The return on equity is positive at 49.21%, but this is due to the negative equity base rather than operational efficiency. The equity ratio is not available due to negative equity, indicating potential financial instability.

Cash Flow

The cash flow statement shows a positive free cash flow growth rate of 30.23% in the TTM, indicating improved cash generation. However, the operating cash flow to net income ratio is negative, reflecting cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is covering net losses, but overall cash flow remains negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	235.81M	221.90M	9.30M	77.65M	69.72M	8.25M
Gross Profit	228.25M	218.02M	6.86M	74.21M	66.60M	5.16M
EBITDA	-643.59M	-436.83M	-565.47M	-397.44M	-533.83M	-465.75M
Net Income	-776.41M	-535.76M	-643.20M	-493.96M	-639.30M	-483.93M
Balance Sheet
Total Assets	1.08B	919.34M	546.38M	623.04M	1.01B	703.59M
Cash, Cash Equivalents and Short-Term Investments	757.34M	681.10M	434.88M	428.27M	787.51M	607.09M
Total Debt	2.68B	1.73B	1.74B	1.72B	1.73B	495.79M
Total Liabilities	2.86B	2.38B	1.89B	1.87B	1.88B	595.70M
Stockholders Equity	-1.79B	-1.46B	-1.35B	-1.25B	-870.41M	57.91M
Cash Flow
Free Cash Flow	-665.87M	-521.66M	-529.03M	-425.81M	-546.18M	-407.23M
Operating Cash Flow	-655.81M	-520.73M	-527.72M	-419.49M	-497.93M	-399.71M
Investing Cash Flow	20.39M	60.78M	54.03M	453.15M	-200.83M	-52.99M
Financing Cash Flow	837.01M	748.46M	451.54M	-13.13M	736.45M	447.19M

BridgeBio Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 49.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Positive. The current price of 49.09 is above the 20-day moving average (MA) of 46.89, above the 50-day MA of 44.24, and above the 200-day MA of 34.69, indicating a bullish trend. The MACD of 1.24 indicates Negative momentum. The RSI at 65.97 is Neutral, neither overbought nor oversold. The STOCH value of 89.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIO.

BridgeBio Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	62 Neutral	$4.30B	74.48	26.63%	―	30.96%	-38.30%
BBIO	53 Neutral	$9.38B	―	35.68%	―	7.62%	-55.29%
RVMD	52 Neutral	$6.59B	―	-46.61%	―	-100.00%	-23.49%
LEGN	48 Neutral	$6.67B	―	-29.70%	―	75.01%	-13.20%
Sector *	47 Neutral	C$212.69M	-1.55	-24.82%	3.11%	19.75%	0.14%
SRPT	46 Neutral	$1.75B	19.61	-4.76%	―	64.89%	-221.56%

BridgeBio Pharma Corporate Events

BridgeBio Pharma Enters Royalty Purchase Agreement

On June 27, 2025, BridgeBio Pharma, Inc. and its subsidiary Eidos Therapeutics, Inc. entered into a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP. Eidos sold certain royalty rights on net sales of products containing acoramidis in the EU to the purchasers for $300 million. This agreement provides BridgeBio with immediate capital while capping the purchasers’ royalty rights and offering security interests in specific assets, potentially impacting the company’s financial strategy and stakeholder interests.

The most recent analyst rating on (BBIO) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.

BridgeBio Pharma Annual Meeting Approves Key Proposals

BridgeBio Pharma held its Annual Meeting on June 20, 2025, where stockholders voted on several key proposals. These included the election of five Class III directors, approval of executive compensation, ratification of Deloitte & Touche LLP as the independent accounting firm, and amendments to the company’s stock option plan and certificate of incorporation. The meeting also approved the adjournment of the meeting if necessary due to insufficient votes.

The most recent analyst rating on (BBIO) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.